Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial.
In a randomly allocated, double-blind, placebo-controlled, cross-over design, 50 infertile patients were treated for 1 month with placebo or a combination of l-arginine aspartate and Pycnogenol (Prelox). Semen samples were examined at 4 week intervals according to WHO criteria. Treatment with Prelox increased significantly the semen volume, concentration of spermatozoa, percentage of motile spermatozoa and percentage of spermatozoa with normal morphology compared with placebo. The placebo had no influence on the parameters of seminological analysis. Intake of Pycnogenol for 1 month improved the fertility index to normal values. After treatment, the fertility index decreased again to infertile status. No unwanted effects were reported. Prelox seems to be a promising alternative to treat patients with mild infertility.
Stanislavov
R
R
Medical University Sofia, Faculty of Medicine, Department of Obstetrics and Gynecology, Sofia, Bulgaria.
Nikolova
V
V
Rohdewald
P
P
D000328:Adult; D001120:Arginine / Q000627:therapeutic use; D001224:Aspartic Acid / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005419:Flavonoids / Q000627:therapeutic use*; D006801:Humans; D007248:Infertility, Male / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts; D055101:Semen Analysis; D013081:Sperm Motility / Q000187:drug effects
D005419:Flavonoids; D010936:Plant Extracts; D001224:Aspartic Acid; C024070:pycnogenols; D001120:Arginine; C024891:arginine aspartate